Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2020; 26(26): 3792-3799
Published online Jul 14, 2020. doi: 10.3748/wjg.v26.i26.3792
Published online Jul 14, 2020. doi: 10.3748/wjg.v26.i26.3792
Two-day enema antibiotic therapy for parasite eradication and resolution of symptoms
Niloufar Roshan, Annabel Clancy, Anoja W Gunaratne, Antoinette LeBusque, Denise Pilarinos, Thomas J Borody, Centre for Digestive Diseases, New South Wales 2046, Australia
Author contributions: Roshan N was involved in data collection, analysis and writing the original draft; Clancy A was involved in supervision, writing, review and editing; Gunaratne AW contributed to the data collection and writing review; LeBusque A performed the data collection and writing review; Pilarinos D was involved in data collection and writing review; Borody TJ contributed to the supervision, writing review and editing; All authors have read and approve the final manuscript.
Institutional review board statement: This study was approved by the institutional ethics committee (CDD19/C02).
Informed consent statement: A waiver of consent was granted for this study. Patients were not required to give informed consent for this study because the analysis used de-identified data that was obtained after each patient agreed to treatment.
Conflict-of-interest statement: : Professor Thomas J Borody has a pecuniary interest in the Centre for Digestive Diseases and has filed patents for antibiotic therapies for parasitic infections. Dr Niloufar Roshan, Dr Annabel Clancy, Dr Anoja Gunaratne, Ms Antoinette LeBusque and Ms Denise Pilarinos have no disclosures.
Data sharing statement: All data requests should be submitted to the corresponding author for consideration.
STROBE statement: The authors have read the STROBE statement-checklist of items, the manuscript was prepared according to the STROBE statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Niloufar Roshan, PhD, Research Fellow, Research, Centre for Digestive Diseases, Level 1, 229 Great North Road, New South Wales 2046, Australia. niloufar.roshanhesari@cdd.com.au
Received: November 19, 2020
Peer-review started: November 19, 2020
First decision: April 2, 2020
Revised: May 9, 2020
Accepted: June 20, 2020
Article in press: June 20, 2020
Published online: July 14, 2020
Peer-review started: November 19, 2020
First decision: April 2, 2020
Revised: May 9, 2020
Accepted: June 20, 2020
Article in press: June 20, 2020
Published online: July 14, 2020
Core Tip
Core tip: Intestinal parasitic infections caused by Blastocystis hominis (B. hominis) and Dientamoeba fragilis (D. fragilis) have the ability to cause illness. This study investigated the effect of a triple antibiotic therapy using 2-d enema infusion for treatment of patients who were positive to B. hominis, D. fragilis or both. A significant reduction in major symptoms as well as parasite eradication were observed post-treatment. Larger clinical trials should further investigate improvements of such therapy using larger volume enemas and alternative delivery routes.